UNSPSC 51422203: Rimexolone

This classification denotes a therapeutic glucocorticoid with the molecular formula C24H34O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O7M2E4264D, chemically known as 11beta-hydroxy-16alpha,17alpha-dimethyl-17-propionylandrosta-1,4-dien-3-one but generally known as rimexolone, which bears US NIH Compound Identifier 39507. European Medicines Agency schedules Rimexolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10323MIG.

UNSPSC 51422203 Rimexolone is a Commodity code, but the most recent state and local opportunity tagged to it involves procurement of naloxone and drug deactivation systems, which falls outside the scope of this specific pharmaceutical product. Rimexolone is an ophthalmic corticosteroid used in eye care, yet the single available recent opportunity addresses overdose-reversal and substance-disposal equipment—a mismatch that signals minimal relevant procurement activity under this code in the state and local market. The code shows little evidence of state and local buying focused on rimexolone or closely related pharmaceutical commodities at this time.

Seminole County, Florida posted an IFB (Invitation for Bid) on June 30, 2026, for procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with a response deadline of July 26, 2023, seeking quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. This opportunity, while tagged to the rimexolone code, represents opioid-management and emergency-response equipment rather than a pharmaceutical product line consistent with the code's nominal scope. Without additional recent opportunities specifically soliciting rimexolone or related ophthalmic corticosteroids from state and local buyers, the code does not demonstrate active or sustained procurement activity relevant to vendors in the pharmaceutical supply chain.